Terguride

Drug Profile

Terguride

Alternative Names: Dironyl; Dironyl maleate; Mysalfon; SH 406; Teluron; Transdihydrolisuride; VUFB 6638; ZK 31224

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer Schering Pharma; Bayer Yakuhin; ErgoNex Pharma; IVAX Pharmaceuticals s.r.o.; Pfizer
  • Class Antiparkinsonians; Antipsychotics; Ergolines; Neuroprotectants; Small molecules; Urea compounds
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperprolactinaemia
  • Discontinued Fibromyalgia; Fibrosis; Parkinson's disease; Pulmonary arterial hypertension; Schizophrenia

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Germany (unspecified route)
  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Netherlands (unspecified route)
  • 11 Aug 2011 Discontinued - Phase-II for Pulmonary hypertension in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top